In the United States there has been an increase in mycobacterial infections that is attributable to the acquired immunodeficiency syndrome (AIDS). Since 1983, when the first case of AIDS was reported in Australia, there have been 523 patients (to June 30, 1987) notified with group-IV AIDS and, of these, 361 (69%) cases have been in New South Wales. Of these 361 notifications, 59 (16%) patients have had concurrent mycobacterial infection. Seven of these patients had Mycobacterium tuberculosis infection and five of these infections occurred in 1986. This means that, in 1986, patients with group-IV AIDS had a rate of infection with Myco. tuberculosis of 3000 per 100,000 population, compared with 5.2 cases per 100,000 population for New South Wales. We sought to determine whether or not there was any unexplained increase in notifications which might be attributable to AIDS. This paper reports cases that were notified to the AIDS and tuberculosis registers, finds that atypical mycobacterial infections are underreported by at least 19.5%, and examines trends in notifications for mycobacterial disease since the onset of the AIDS epidemic. It also raises the importance of appropriate measures to protect health workers from tuberculosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5694/j.1326-5377.1988.tb116331.x | DOI Listing |
Travel Med Infect Dis
January 2025
Servicio de Infectología, Hospital Militar Central, Bogotá D.C., Colombia; Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá, D.C., Colombia. Electronic address:
Proc Natl Acad Sci U S A
February 2025
U.S. Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD 20910.
HIV-1 envelope broadly neutralizing antibodies represent a promising component of HIV-1 cure strategies. To evaluate the therapeutic efficacy of combination monoclonal antibodies (mAbs) in a rigorous nonhuman primate model, we tested different combinations of simian immunodeficiency virus (SIV) neutralizing mAbs in SIVmac251-infected rhesus macaques. Antiretroviral therapy-suppressed animals received anti-SIV mAbs targeting multiple Env epitopes spanning analytical treatment interruption (ATI) in 3 groups (n = 7 each): i) no mAb; ii) 4-mAb combination; and iii) 2-mAb combination.
View Article and Find Full Text PDFJMIR Public Health Surveill
January 2025
Monitoring, Evaluation, and Learning Platform USAID, Jakarta, Indonesia.
Background: Indonesia's vast archipelago and substantial population size present unique challenges in addressing its multifaceted HIV epidemic, with 90% of its 514 districts and cities reporting cases. Identifying key populations (KPs) is essential for effectively targeting interventions and allocating resources to address the changing dynamics of the epidemic.
Objective: We examine the 2022 mapping of Indonesia's KPs to develop improved HIV and AIDS interventions.
Cureus
December 2024
Internal Medicine, Thumbay University Hospital, Ajman, ARE.
, the bacteria that causes syphilis, is typically acquired through sexual contact but can also be transmitted transplacentally (through the placenta), causing congenital infection. Syphilis in pregnancy is a major contributing factor to perinatal morbidity and mortality. Untreated neonates may develop complications affecting the central nervous system, bones, joints, teeth, eyes, and skin.
View Article and Find Full Text PDFComput Biol Med
January 2025
Department of Chemistry, Graduate University of Advanced Technology, Kerman, Iran.
Designing and employing enzyme inhibitors against viral enzymes is one of the innovative and efficient approaches to treating viral diseases. These inhibitors can disrupt the viral replication cycle by deactivating vital enzymes, thereby curbing the spread of viral infections by reducing their population. So far, inhibitors have been designed, validated, and introduced for these enzymes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!